Prevention, diagnosis and treatment of cancer-associated thromboembolism

Czech version

Authors: P. Tesařová ¹; D. Karetová ²; J. Hirmerová ³; R. Malý ⁴; S. Vokurka ⁵; T. Kvasnička ⁶; P. Kessler ⁷; P. Ďulíček ⁸; J. Gumulec ⁹; V. Maňásek ¹⁰; J. Cvek ¹¹; J. Prausová ¹²; B. Melichar ¹³; J. Kopecký ¹⁴; J. Kleinová ¹⁵; P. Aulický ¹⁶; J. Blatný ¹⁷; M. Penka ¹⁸
Authors‘ workplace: Radioterapeutický ústav FNB a 1. LF UK, Onkologická klinika VFN v Praze ¹; II. interní klinika – kardiologie a angiologie 1. LF UK, a VFN v Praze ²; 2. interní klinika LF UK a FN Plzeň ³; 1. interní klinika LF UK a FN Hradec Králové ⁴; Onkologická a radioterapeutická klinika FN Plzeň ⁵; Trombotické centrum, VFN Praha ⁶; Oddělení hematologie a transfuziologie, Nemocnice Pelhřimov ⁷; IV. interní hematologická klinika, FN Hradec Králové ⁸; Klinika hematoonkologie FN Ostrava ⁹; Onkologické oddělení Nemocnice Agel, Nový Jičín ¹⁰; Onkologická klinika LF OU a FN Ostrava ¹¹; Onkologická klinika 2. LF UK a FN Motol, Praha ¹²; Onkologická klinika FN Olomouc ¹³; Onkologická klinika LF UK a FN Hradec Králové ¹⁴; Masarykův onkologický ústav – Interní oddělení Masarykova onkologického ústavu, Brno ¹⁵; ARO Nemocnice milosrdných bratří, Brno ¹⁶; Klinika dětské onkologie FN Brno ¹⁷; Oddělení klinické hematologie, FN Brno ¹⁸
Published in: Transfuze Hematol. dnes,29, 2023, No. 1, p. 61-67.
Category:
doi: https://doi.org/10.48095/cctahd202361

Overview

Doporučení vychází současně jako samostatná kapitola Modré knihy České onkologické společnosti 2023

Česká kooperativní skupina pro prevenci, léčbu a diagnostiku CAT:

Sources

1. Xu X, Chlebowski RT, Shi J, Barac A, Haque R. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. Breast Cancer Res Treat. 2019; 174 (3): 785–794.

2. Guo Z, Huang Y, Gong L, et al. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2018; 21 (4): 451–460.

3. Li LJ, Chen DF, Wu GF, et al. Incidence and risk of thromboembolism associated with bevacizumab in patients with non-small cell lung carcinoma. J Thorac Dis. 2018; 10 (8): 5010.

4. Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high‐risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013; 119 (3): 648–655.

5. Zhu VW, Zhao JJ, Gao Y, et al. Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis. Lung Cancer. 2021; 157: 147–155.

6. Ratib S, Walker AJ, Card TR, Grainge MJ. Risk of venous thromboembolism in hospitalised cancer patients in England – a cohort study. J Hematol Oncol. 2016; 9 (1): 1–9.

7. Masoud V, Pagès G. Targeted therapies in breast cancer: New challenges to fight against resistance. World J Clin Oncol. 2017; 8 (2): 120.

8. Guo Z, Huang Y, Gong L, et al. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2018; 21 (4): 451–460.

9. Semrad TJ, O‘Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007; 106 (4): 601–608.

10. Porfidia A, Giordano M, Sturiale CL, et al. Risk of intracranial bleeding in patients with primary brain cancer receiving therapeutic anticoagulation for venous thromboembolism: A meta‐analysis. Brain Behav. 2020; 10 (6): e01 638.

11. Peterson EA, Lee AYY. Update from the clinic: what‘s new in the diagnosis of cancer-associated thrombosis? Hematology Am Soc Hematol Educ Program. 2019; 2019 (1): 167–174.

12. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020; 38 (5): 496–520.

13. Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021; 5 (4): 927–974.

14. Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021; 160 (6): e545–e608.

15. Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022; 23 (7): e334–e347.

16. Khorana AA, DeSancho MT, Liebman H, Rosovsky R, Connors JM, Zwicker J. Prediction and prevention of cancer-associated thromboembolism. Oncologist. 2021; 26 (1): e2–e7.

Labels

Haematology Internal medicine Clinical oncology

Editorial

Leukemic stem cell surface markers in chronic myeloid leukaemia

Blast phase of chronic myeloid leukaemia

Vascular adverse events in chronic myeloid leukaemia patients during tyrosine kinase inhibitor therapy in daily clinical practice – analysis from the INFINITY database

Rare and unfavorable course of chronic myeloid leukemia – a case report and review of the literature

Recommendations for thrombotic risk stratification and targeted thromboprophylaxis in women during assisted reproduction

Recommendations of the Czech Society of Haematology for the diagnosis and treatment of immune thrombocytopenia in adults

Symposium and workshop – actual challenges and implementation of new technologies in the treatment of chronic myeloid leukaemia

Fixní délka léčby CLL – realita, nebo fikce?

Jubileum primářky Lenky Walterové

Article was published in

Transfusion and Haematology Today

2023 Issue 1